Neurocrine upped to overweight by Piper, sees '568 as still viable08/30/2024 [ad_1] Neurocrine upped to overweight by Piper, sees ‘568 as still viable [ad_2] Source: Seekingalpha
Neurocrine stock dips even as schizophrenia drug meets main goal in study08/29/2024 [ad_1] Neurocrine stock dips even as schizophrenia drug meets main goal in study [ad_2] Source: Seekingalpha
